Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Jan 12, 2021 8:07pm
140 Views
Post# 32282032

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Excellent

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ExcellentLet's not forget one thing. I am sure there was no financing deal available to Thera when it was at 14$, maybe not even a deal at 7$. This why they went with the convertible back then, because they thought that Trogarzo would be a success and that they would do a financing at a better price later. The same applies now. It is not because the stock would have been higher, let's say 6$, that a financing deal would have been on the table at that price. The brokers doing these deals want them at a discounted price, otherwise there is no deal. They are willing to take a risk, but they want a good upside margin. In the end, the price of a financing comes down to the demand for the stock. It seems obvious that in this case the demand was not very high.


1998novl wrote: I get it, you wish it was done at $8 or $10, so do I. I wish instead of the convertible they issued equity at $14. /quote]

<< Previous
Bullboard Posts
Next >>